nasal
NAD+ Nasal
An intranasal NAD+ formulation engineered for direct CNS delivery via olfactory and trigeminal nerve pathways — bypassing hepatic first-pass metabolism to target neuronal NAD+ pools declining with age and neurodegeneration.
For research and laboratory use only. Not for human consumption.
Subscribe & save: $127
Quantity
Add 1 more to save 10% per unit
Technical Data
Specifications
Technical Details
Bulk Pricing
Volume Pricing Guide
Quality Assurance
Certificate of Analysis
Certificate of Analysis
COA documentation is being prepared for this product.
Contact research@roehnrx.com for batch-specific testing data.
Research Overview
About NAD+ Nasal
NAD+ Nasal is a preservative-free intranasal formulation of nicotinamide adenine dinucleotide designed to exploit the unique anatomy of the nasal epithelium for brain-targeted delivery. The olfactory mucosa and trigeminal nerve endings provide direct neural conduits to the CNS, potentially circumventing both the blood-brain barrier and first-pass hepatic metabolism that limit the central bioavailability of systemically administered NAD+.
The rationale for brain-targeted NAD+ delivery is grounded in evidence that neuronal NAD+ levels decline disproportionately with aging and in neurodegenerative disease states. Neurons carry exceptionally high metabolic demands and are acutely sensitive to mitochondrial dysfunction — making NAD+ availability a rate-limiting factor for sirtuin-mediated neuroprotection, PARP-dependent DNA repair, and mitochondrial electron transport chain efficiency in CNS tissue.
Intranasal delivery of neuroactive compounds has been validated clinically for insulin, desmopressin, and several experimental neuroprotective agents. ROEHN's NAD+ nasal spray provides a non-injectable route for research protocols focused specifically on CNS NAD+ biology, cognitive endpoints, neuroinflammation markers, and fatigue-related outcomes.
